Korea Investment CORP Increases Stake in Eli Lilly and Company

The investment firm now owns over $516 million in Eli Lilly shares.

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

According to a recent SEC filing, Korea Investment CORP increased its position in pharmaceutical giant Eli Lilly and Company by 5.1% during the 3rd quarter of 2026. The firm now owns 676,396 shares of Eli Lilly's stock, valued at approximately $516.09 million and making up around 1.1% of Korea Investment CORP's total holdings.

Why it matters

Eli Lilly is one of the world's leading pharmaceutical companies, known for developing innovative medicines across a range of therapeutic areas. Korea Investment CORP's increased stake in the company signals confidence in Eli Lilly's long-term growth prospects and ability to deliver returns for investors.

The details

Korea Investment CORP acquired an additional 33,060 shares of Eli Lilly during the 3rd quarter, bringing its total position to 676,396 shares. This makes Eli Lilly the 12th largest holding in Korea Investment CORP's portfolio, accounting for around 1.1% of the firm's total assets under management.

  • Korea Investment CORP increased its Eli Lilly stake during the 3rd quarter of 2026.

The players

Korea Investment CORP

A major South Korean sovereign wealth fund that manages over $500 billion in assets globally.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana that develops and commercializes a broad range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

Korea Investment CORP's increased stake in Eli Lilly underscores the pharmaceutical company's strong position in the global market and its potential for continued growth and profitability. This investment signals that major institutional investors remain bullish on Eli Lilly's long-term prospects.